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Background: We report on a patient with genetically confirmed overlapping diagnoses of CMT1A and FSHD. This
case adds to the increasing number of unique patients presenting with atypical phenotypes, particularly in FSHD.
Even if a mutation in one disease gene has been found, further genetic testing might be warranted in cases with
unusual clinical presentation.
Case presentation: The reported 53 years old male patient suffered from walking difficulties and foot
deformities first noticed at age 20. Later on, he developed scapuloperoneal and truncal muscle weakness,
along with atrophy of the intrinsic hand and foot muscles, pes cavus, claw toes and a distal symmetric
hypoesthesia. Motor nerve conduction velocities were reduced to 20 m/s in the upper extremities, and not
educible in the lower extremities, sensory nerve conduction velocities were not attainable. Electromyography
showed both, myopathic and neurogenic changes. A muscle biopsy taken from the tibialis anterior muscle
showed a mild myopathy with some neurogenic findings and hypertrophic type 1 fibers. Whole-body muscle
MRI revealed severe changes in the lower leg muscles, tibialis anterior and gastrocnemius muscles were highly
replaced by fatty tissue. Additionally, fatty degeneration of shoulder girdle and straight back muscles, and
atrophy of dorsal upper leg muscles were seen. Taken together, the presenting features suggested both, a
neuropathy and a myopathy. Patient’s family history suggested an autosomal dominant inheritance.
Molecular testing revealed both, a hereditary motor and sensory neuropathy type 1A (HMSN1A, also called
Charcot-Marie-Tooth neuropathy 1A, CMT1A) due to a PMP22 gene duplication and facioscapulohumeral muscular
dystrophy (FSHD) due to a partial deletion of the D4Z4 locus (19 kb).
Conclusion: Molecular testing in hereditary neuromuscular disorders has led to the identification of an increasing
number of atypical phenotypes. Nevertheless, finding the right diagnosis is crucial for the patient in order to
obtain adequate medical care and appropriate genetic counseling, especially in the background of arising curative
therapies.
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Hereditary motor and sensory neuropathy (HMSN),
also called Charcot-Marie-Tooth (CMT) disease, is the
most common inherited neuromuscular disorder with
an estimated prevalence of 1:2,500 [1]. Roughly one
third of all cases are caused by an autosomal dominant
inherited 1.5 Megabase (Mb) tandem duplication en-
compassing the peripheral myelin protein 22 gene
(PMP22) on chromosome 17p11.2-12 which encodes an
important component of peripheral nervous system
myelin [2-4]. Phenotypically, patients show a symmetric
and distally pronounced muscle weakness and sensory
deficits affecting the feet and lower legs and, to a lesser
extent, the hands and forearms. Progressive muscle at-
rophy results in “steppage” gait and secondary foot de-
formities and can lead to severe disablement. Sensory
deficits and paraesthesia are usually less prominent
than in other neuropathies. Electrophysiology is an im-
portant tool for diagnosis and classification into demye-
linating CMT1 (motor conduction velocities (MCVs) of
median nerve <38 m/s) and axonal CMT2 (median
nerve MCV > 38 m/s). Supportive treatment includes
rehabilitative therapy and surgical treatment of skeletal
deformities and soft-tissue abnormalities in a multidis-
ciplinary approach [5,6]. Curative therapeutic options
are under investigation.
Autosomal dominant facioscapulohumeral muscular
dystrophy (FSHD) is the third most common muscu-
lar dystrophy with an estimated prevalence of about
1:20,000 in Europe [7]. The four main diagnostic criteria
defining FSHD are (1) onset in facial or shoulder mus-
cles with sparing of extraocular, pharyngeal and lingual
muscles and the myocardium, (2) facial weakness in
more than half of the affected family members, (3) auto-
somal dominant inheritance and (4) evidence of a myo-
pathic disease in electromyography and muscle biopsy
[8]. The causative gene defect in the large majority
(>95%) of FSHD patients is a contraction of a repetitive
element on chromosome 4q35 known as D4Z4 to 1 to
10 units (in healthy individuals 11 to 100 units). Because
FSHD is apparently not due to a conventional mutation
within a neighboring protein-coding gene, the exact
pathophysiological mechanism of the repeat loss causing
muscle disease is unknown [9]. The phenotypic spectrum
is wide, even in the same family, showing a great variabil-
ity in the level of impairment and disease progression.
Therefore, it is still a diagnostic challenge to correctly
diagnose FSHD since a broad clinical diversity results
from a shortened D4Z4 locus.
With the advent of new causative therapeutic options
finding a patient’s correct diagnosis is essential. The case
presented here shows a new phenotype of two overlap-
ping neuromuscular diseases which emphasizes the diag-
nostic challenges.Case presentation
Methods
The patient was clinically and electrophysiologically ex-
amined by the authors.
An open muscle biopsy was performed at the age of 21
after first clinical symptoms occurred. Standard histo-
logical examination was carried out as described previ-
ously [10] and the muscle biopsy specimens were revisited
after disease progression.
Whole-body muscle magnetic resonance imaging
(MRI) was performed using a 3.0-T MR system. A rou-
tine muscular protocol containing axial T1-weighted
(T1w) spin echo sequences was used (slice thickness:
6 mm). The protocol additionally included coronal and
axial planes at four levels covering the whole body. The
left distal pelvic muscles and proximal femoral muscles
could not be examined as the patient had a hip implant.
Using MLPA (Multiplex Ligation-dependent Probe
Amplification)-analysis (MRC-Holland P033) the PMP22
gene was searched for deletions and duplications. FSHD
diagnosis was established by Southern blot analysis for
the D4Z4 locus as reported elsewhere [11]. Furthermore,
the mutation-hot spot region of the myotilin gene was
examined by direct sequencing of exon 2 (NM_006790).
This case report was exempt as part of the patient’s stand-
ard care. The patient consented to all performed diagnostic
analyses as part of a standard diagnostic work-up and care
as well as the publication of his clinical data, images (clinical
photographs, MRI, muscle biopsy) and videos. However, he
preferred to have his face made unrecognizable on the pho-
tos. Additionally, his family members gave permission for
publication of their medical histories.
Clinical data
Childhood and adolescence were reported normal. First
clinical symptoms were noted at age 20 with pes cavus,
claw toes and walking difficulties. During the 5th decade,
weakness of arm elevation and distal weakness of hands
affecting the dorsal interossei with reduced abduction in
the metacarpophalangeal (MCP) joints and a weakness
in thumb abduction occurred. The patient reported mild
hypoesthesia of fingers and toes and he had marked dif-
ficulties to button up his shirt. He walked unaided and
maximum walking distance was not impaired.
Clinical examination revealed a scapuloperoneal pheno-
type associated with pectoralis muscle atrophy, truncal
weakness and scapular winging. The patient was not able
to lift his arms above the horizontal level. There was no
facial and bulbar weakness and no Beevor’s sign. He did
not suffer from scoliosis or contractures. Standing or
walking on toes or heels was not possible and in heel to
toe walking (tandem gait) an unsteady gait, probably due
to sensory loss, was observed. Additionally, lower limb
weakness (extensor digitorum MRC 4/5, abductor pollicis
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MRC 2/5) along with marked muscle atrophy was found.
Distal symmetric hypoesthesia and the described foot de-
formities were observed (Figure 1). Deep tendon reflexes
were absent. Needle EMG showed mild myopathic
changes in proximal muscles such as M. biceps brachii
and M. iliopsoas and neurogenic changes in tibialis anter-
ior muscles. Nerve conduction velocities in upper limb
motor nerves showed a demyelinating neuropathy (median
nerve 17 m/s, DML 9.5 ms; ulnar nerve 21 m/s, DML
7.2 ms). Compound motor action potentials (CMAPs)
were normal in amplitude without signs of conduction
block or temporal dispersion. Lower limb motor nerves
were not educible. Sensory nerve conduction velocities
were repeatedly not attainable. CK levels were elevated up
to 300 U/l (normal value < 180).
In summary, the patient presented with a scapulope-
roneal weakness and atrophy, foot deformities along
with sensorimotor demyelinating neuropathy and mild
hyerCKemia.Figure 1 Clinical phenotype. The patient shows a scapuloperoneal patte
winging (A, C). The arms cannot be lifted over the horizontal level (A). At
are pronounced (B).Family history
The patient has three siblings (two sisters age 49 and 61,
and one brother age 51). One sister and her daughter
suffer from a sensorimotor neuropathy, but were not
available for further investigations. The parents were
reported healthy, however, the father died early at age 49
due to an accident and the mother died at age 68 due to
gastric cancer. The mother’s four siblings and their pro-
genies as well as the patient’s grandparents were
reported healthy (Figure 2).MRI
The muscle MRI showed the most severe changes in the
lower leg muscles. Tibialis anterior and gastrocnemius
muscles were largely replaced by fatty tissue. Besides,
fatty degeneration of serratus, latissimus dorsi and
straight back muscles (data not shown) as well as atro-
phy of dorsal upper leg muscles, mainly biceps femoris
and semimembranosus, were seen (Figure 3).rn of muscle wasting and weakness with pectoral wasting and scapular
the lower extremities, lower leg atrophy (D), pes cavus and claw toes
Figure 2 Family history. The patient’s parents died early and had no symptoms of muscle weakness or neuropathy. Neither did the mother’s
four siblings and their progenies. Besides our patient one of his sisters and her older daughter show similar symptoms of peripheral neuropathy
with foot deformities and gait difficulties. No symptoms of muscle wasting or weakness occurred in these two family members until now.
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An open muscle biopsy of the left tibialis anterior muscle
was performed at the age of 21. It showed mild myopathic
alterations with fiber splitting and increase of endomysial
connective tissue, however some small neurogenic-like
muscles fibers and numerous hypertrophic type I fibers
were seen. This biopsy did not reveal any necrotic fibers
or inflammatory changes (Figure 4A). ATPase staining re-
vealed no fiber type grouping, but a type-1 fiber predom-
inance of up to 80%, as commonly seen in anterior tibial
muscle (Figure 4B). Trichrome staining showed no ragged
red fibers. No myofibrillar or mitochondrial changes were
detected.Figure 3 MR imaging. Whole-body MRI shows nearly complete fatty atrop
as moderate fatty replacement of muscle tissue in the soleus muscle (A, C
semimembranosus and M. biceps femoris (B). Gluteal muscles revealed mil
scapular fixators (Mm. serrati and Mm. latissimi dorsi) and axial back muscle
were not examined as the patient had a hip implant.Molecular analysis
Molecular analysis of the PMP22 gene showed the typical
duplication encompassing the PMP22 gene on chromo-
some 17p11.2-12 confirming the diagnosis of CMT1A. No
mutations were found in exon 2 of the myotilin gene. A
shortened chromosome 4q-specific fragment of 19 kb in
the D4Z4 locus (FSHD repeat) and the FSHD-related 4qA
haplotype were observed leading to the diagnosis of FSHD.
Discussion
Both hereditary sensorimotor neuropathy due to PMP22
duplication (CMT1A) and facioscapulohumeral muscu-
lar dystrophy (FSHD) due to a shortened fragment ofhy of the tibialis anterior muscles and the Mm. gastrocnemii, as well
). Atrophy of the dorsal upper leg muscles is pronounced in the M.
d fatty degeneration. Additionally, fatty muscle degeneration of
s was detected (data not shown). The pelvis and proximal upper legs
Figure 4 Muscle biopsy. (A) H&E staining of a muscle biopsy of the left anterior tibial muscle with mild myopathic changes indicated by muscle
fiber splitting and increase in endomysial connective tissue. Additionally, in the ATPase pH 4.1 staining (B), a type I fiber predominance without
evidence of fiber type grouping and numerous hypertrophic type I fibers are notable. Bars in A and B adjusted to 50 μm.
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patient. To the best of our knowledge this is one of only
three published cases describing coincidence of CMT1A
and FSHD.
Recent epidemiological data suggest that the frequency
of CMT1A is around 1:7,500 [4] while the frequency of
FSHD is estimated at 1:20,000 [7]. Thus, the chance of
being affected by both disorders is about 1:150,000,000.
In the patient’s family history his sister and her daugh-
ter were suggestive of CMT1A as well. However, since
both parents have died and no DNA samples of further
family members were available, segregation could not be
proven. Our patient showed typical symptoms of this
generalized, primarily demyelinating neuropathy with re-
duced nerve conduction velocities, distal hypoesthesia
and distal muscle atrophy leading to steppage gait and
foot deformities like pes cavus und claw toes [1].
Since additional features like proximal muscle weak-
ness of the shoulder girdle, myopathic changes in muscle
biopsy specimen and EMG analysis were suggestive of
additional primary involvement of the skeletal muscle
genetic analyses were extended to include frequent
forms of muscular dystrophies and myopathies. FSHD
diagnosis was established by Southern blot analysis for
the D4Z4 locus showing contraction of the repeat
(19 kb) and a FSHD-related 4qA haplotype. It remains
unclear if FSHD results from a de novo mutation occur-
ring in 10% to 30% of all cases [12] or from familial in-
heritance as we cannot rule out the possibility of an
undiagnosed mild presentation in other family members.
Until now, the pathogenic relevance of the D4Z4 dele-
tion has not been fully clarified and has been questioned
in recent studies [13]. However, in addition to the clin-
ical findings, electromyography in our patient revealed
mild myopathic changes in proximal muscles along with
the myopathic changes in the muscle biopsy specimen.
Along with shortening of the D4Z4 locus to 19 kb on
EcoRI + BlnI double digestion, FSHD is likely to be
causative for the additional myopathy.The classical FSHD phenotype was described in 1884
by Landouzy and Dejerine with facial weakness, shoulder
girdle and pectoral muscle weakness and atrophy, in
some cases resulting in subsequent impairment of pelvic
and lower leg muscles [14]. But clinical variability has
long been recognized in neuromuscular disorders. This
has become most obvious with the advent of molecular
genetic testing showing that identical molecular defects
can result in diverse clinical presentations. This is espe-
cially true for FSHD where several unusual phenotypes
and atypical morphological features ranging from
hyperCKemia, severe muscle pain, facial-sparing, hyper-
trophic cardiomyopathy, camptocormia, distal and axial
myopathy, along with atypical morphological changes
such as vacuolar and/or inflammatory myopathy, ne-
maline rods, and deficiency of complex III of the mito-
chondrial respiratory chain were reported [15-23]. Our
patient provides further evidence for this variability by
not fulfilling all four major diagnostic criteria for diagno-
sis of FSHD as described above [8]. Autosomal dominant
inheritance cannot be proven since the parents were not
available for molecular testing, and facial weakness was
not seen.
Interfamilial and intrafamilial clinical variability has
also been observed in CMT [24,25] including cases of
demyelinating CMT with scapuloperoneal distribution of
motor impairment reported in the 1980s [26,27]. In con-
trast to our case, these cases were confined to clinical
findings since molecular genetic testing was not yet
available in the 1980s. Harding and Thomas described a
constellation of clinical symptoms similar to our patient
but with striking wasting of both deltoid muscles which
is rather uncommon in FSHD so that we cannot exclude
that this patient suffered from another scapuloperoneal
myopathy.
In addition to stochastic effects, environmental influ-
ences, allelic variation, modifier genes, somatic mosaicism
and complex genetic and environmental interactions [28],
some of this variability might be caused by concomitant
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In FSHD, such overlapping syndromes have been de-
scribed several times in literature. Association with patho-
genic mutations in other genes have been reported in
cases of patients with mitochondrial myopathy/FSHD,
Becker muscular dystrophy/FSHD, Duchenne muscular
dystrophy/FSHD, Leber’s hereditary optic neuropathy/
FSHD and caveolinopathy/FSHD determining overlapping
phenotypes [15,29-33]. For CMT1A, concomitant muta-
tions in the PMP22 gene and the Connexin32 gene (caus-
ing CMTX), the DMPK1 gene (DM1 myotonic dystrophy)
and the ABCD1 gene (adrenomyeloneuropathy) have been
described to produce peculiar phenotypes [34]. In ad-
dition, a combination of CMTX with Becker muscular
dystrophy has been reported [35], causing both, general-
ized weakness and CK elevation as typical phenotype for a
muscular dystrophy as well as foot deformity, decreased
tendon reflexes and sensory loss due to a mutation in the
Connexin32 gene.
There is one further report similar to ours on one
family suffering from CMT1A and FSHD [36]. Auer-
Grumbach et al. reported on this family affected by gen-
etically confirmed CMT1A with scapuloperoneal motor
deficit but conflicting data concerning the concomitant
presence of FSHD. Co-segregation of FSHD in this fam-
ily was unconvincing and haplotype analysis on chromo-
some 4q was not performed as it was not described in
the paper. In contrast to our report, no muscle histology
was performed and EMG revealed a mild chronic neuro-
genic pattern in proximal and distal muscles. However,
our patient showed myopathic changes assessed by elec-
tromyography and muscle biopsy which further support
the molecular diagnosis of FSHD.
In our patient a contracted fragment of 19 kb in the
D4Z4 locus was detected. It is generally accepted that
there is a correlation between clinical severity and size
of the D4Z4 repeat: small repeats stand for early age at
onset and severe clinical course, whereas larger repeats
mean later age at onset and milder course [37]. Al-
though the patient reported here carries a repeat size
usually expected to result in a moderately severe pheno-
type with onset in the 1st or 2nd decade, he showed only
mild symptoms of shoulder girdle weakness developing
in the second half of life without facial or proximal leg
muscle impairment until now. There is no obvious
explanation for the unexpectedly mild phenotype in our
patient and in contrast, the association of FSHD with
X-linked CMT and Duchenne muscular dystrophy leads
to severe infantile phenotypes [31,38]. Butefisch et al.
described a further patient with the combination of
CMT1A and FSHD in 1998 [39]. This female patient
inherited CMT1A from her father and FSHD from her
mother and this comorbidity resulted in severe general-
ized weakness, respiratory insufficiency and early death.However, according to the information given in the pa-
per, only the diagnosis of CMT1A was proven by mo-
lecular testing but not the FSHD, neither in the patient
nor in relatives. Thus, we cannot exclude the possibility
that another progressive muscular dystrophy might be
causative for this devastating clinical course in this
patient.
All in all, too few “double trouble” patients are known
to draw significant conclusions on how concomitant
genetic conditions modify each other’s severity and pro-
gression in these patients. Nevertheless, the number of
cases with genetically proven double trouble is likely to
increase with the availability of improved genetic testing
and whole exome or genome sequencing methods. This
will result in an even broader variety of atypical clinical
pictures but may also help to understand interference at
the phenotypic, genetic and epigenetic levels having a
direct impact on medical care and genetic counseling.
Conclusion
Our case reports on a patient with genetically confirmed
overlapping diagnoses of CMT1A and FSHD. It adds to
the increasing number of unique patients presenting
with atypical and overlapping phenotypes, particularly in
FSHD. Even if a mutation in a disease gene has been
found, further genetic testing might be warranted in
cases with unusual clinical presentation having a direct
impact on medical care and genetic counseling.
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